Skip to content
Skip to main content

About this free course

Become an OU student

Download this course

Share this free course

Challenging ideas in mental health
Challenging ideas in mental health

Start this free course now. Just create an account and sign in. Enrol and complete the course for a free statement of participation or digital badge if available.

References

Agrawal, P. (1978) ‘Diazepam addiction: A case report’, Canadian Psychiatric Association Journal, No. 23, pp. 35–7.
Appleby, L. et al. (2018) ‘The national confidential inquiry into suicide and safety in mental health. Annual report: England, Northern Ireland, Scotland, Wales’, Manchester, University of Manchester.
Baxter, C., Poonia, K., Ward, L. and Nadirshaw, Z. (1990) Double Discrimination: Issues and Services for People with Learning Difficulties from Black and Minority Ethnic Communities, London, King’s Fund Centre.
Bentall, R.P. (1992) ‘A proposal to classify happiness as a psychiatric disorder’, Journal of Medical Ethics, Vol. 18, pp. 94–8.
Breggin, P. (1993) Toxic Psychiatry: Drugs and Electroconvulsive Therapy: The Truth and the Better Alternatives, London, Fontana.
Busfield, J. (1986) Managing Madness: Changing Ideas and Practice, London, Hutchinson.
Cobb, A. (2001) Mind’s Yellow Card for Reporting Drug Side Effects: A Report of Users’ Experiences, London, Mind.
Department of Health (2001) National Confidential Inquiry into Homicide and Suicide by People with Mental Illness, London, DH.
Department of Health (2004) ‘Prescription Statistics’.
Dewan, V. (2001) ‘Life support’ in Read, J. (ed.) Something Inside So Strong: Strategies for Surviving Mental Distress, London, Mental Health Foundation, pp. 44–9.
Douglas, M. (2013) Risk and blame. London, Routledge.
Doward, J. and McKie, R. (2004) ‘Revealed: secret plan to push ‘‘happy’’ pills’, Observer, 7 November, pp. 6–7.
Disability Rights Commission (n.d.) ‘A dialogue: ‘‘Can mental health service users benefit from disability rights?’’’ (Transcript of taped conversation between Abina Parshad-Griffin and Liz Sayce), London, DRC.
Galynker, I., & Galynker, I. I. (2017) The suicidal crisis: clinical guide to the assessment of imminent suicide risk. Oxford, Oxford University Press.
Glaxo (1991) ‘Glaxo cultivates the NHS ground’, Pharmaceutical Journal, Vol. 247, p. 6664.
Johnstone, I. (1989) Users and Abusers of Psychiatry: A Critical Look at Traditional Psychiatric Practice, London, Routledge.
Johnstone, L. (1989) Users and Abusers of Psychiatry: A Critical Look at Traditional Psychiatric Practice, London, Routledge.
McManus, S., Lubian, K., Bennett, C., Turley, C., Porter, L., Gill, V., Gunnell, D. and Weich, S. (2019) Suicide and self-harm in Britain: researching risk and resilience using UK surveys. London, NatCen.
Medicines and Healthcare Products Regulatory Agency/MHRA (2003) ‘Monitoring the safety and quality of medicines: The Yellow Card Scheme’.
Metzl, J.M. (2003) Prozac on the Couch, Durham, N.C., Duke University Press.
Mintz, M. (1965) The Therapeutic Nightmare, Boston, Houghton Mifflin.
Mosher, L. (1999) ‘A pharmaceutical too far’, Openmind, Vol. 100, Nov/Dec, pp. 16–17.
NHS (2020) ‘Prescription Cost Analysis - England 2019 – Additional Tables (Table A9)’. Available at: https://www.nhsbsa.nhs.uk/ statistical-collections/ prescription-cost-analysis-england/ prescription-cost-analysis-england-2019 [Tip: hold Ctrl and click a link to open it in a new tab. (Hide tip)] (Accessed: 8 March 2021).
National Institute for Clinical Evidence (2002) ‘First clinical guideline from NICE sets out recommendations for NHS care in schizophrenia’, press release 2002/062, 4 December.
National Institute for Health and Care Excellence (2021) ‘British National Formulary/BNF – Drugs – FLUOXETINE’. Available at: https://bnf.nice.org.uk/ medicinal-forms/ fluoxetine.html#PHP77887 (Accessed: 8 March 2021).
Perkins, R. (2003) ‘On the question of genes ...’, Openmind, Vol. 120, Mar/Apr, p. 6.
Rogers, A. and Pilgrim, .D. (2003) Mental Health and Inequality, Basingstoke, Palgrave.
Rose, D. (2002) ‘Whose medical model?’, Openmind, Vol. 113, Jan/Feb, pp. 20–1.
Ross, A. M., Morgan, A. J., Jorm, A. F. and Reavley, N. J. (2019) ‘A systematic review of the impact of media reports of severe mental illness on stigma and discrimination, and interventions that aim to mitigate any adverse impact’, Social Psychiatry and Psychiatric Epidemiology, vol. 54, no. 1, pp. 11-31.
Scull, A. (1984) Decarceration: Community Treatment and the Deviant: A Radical View, 2nd edition, Cambridge, Polity Press.
Shaw, I. and Woodward, L. (2017) ‘The medicalisation of unhappiness? The management of mental distress in primary care’ in Shaw, I. and Kauppinen, K. (eds) Conceptualising Health and Illness: European Perspectives, Aldershot, Ashgate, pp. 125–38.
Shorter, E. (1997) A History of Psychiatry: From the Era of Asylum to the Age of Prozac, Toronto, John Wiley.
Sibley, D. (1995) Geographies of Exclusion: Society and Difference in the West, London, Routledge.
Silberman, E. et al. (2020) ‘Benzodiazepines: It's time to return to the evidence’ The British Journal of Psychiatry, 1-3.
Wainwright, J., McKeown, M., and Kinney, M. (2019) ‘“In these streets”: the saliency of place in an alternative black mental health resource centre’, International Journal of Human Rights in Healthcare, vol. 13, no. 1, pp. 31-44.
Waldron, I. (1977) ‘Increased prescribing of Valium, Librium and other drugs – an example of economic and social factors in the practice of medicine’, International Journal of Health Services, Vol. 7, No. 41.